Cystic Fibrosis Therapeutics Market Size Worth $13.9 Billion By 2025: Grand View Research, Inc.

Tuesday, June 27, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, June 27, 2017 /PRNewswire/ --

The global cystic fibrosis therapeutics market is expected

to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable
initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

     (Logo: )

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Browse full research report with TOC on "Cystic Fibrosis (CF) Therapeutics Market Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration, By Region, And Segment Forecasts, 2014 - 2025" at:

Further key findings from the report suggest: 

  • The global CF therapeutics market size was estimated at USD 3,560.5 million in 2016 and is expected to grow at a CAGR of 16.7% from 2017 to 2025
  • The CFTR modulator segment emerged as the largest segment in 2016 and the same segment is anticipated to witness fastest growth over the next 8 years owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.
  • Oral route of administration emerged as the largest segment with revenue of USD 2,266.4 million due to the ease of administration and convenience
  • North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,
  • The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Browse related reports by Grand View Research: 

  • Biotechnology Reagents Market -
  • Kidney Cancer Drugs Market -
  • ePharmacies Market -
  • Biopharmaceutical Market -

Grand View Research has segmented the cystic fibrosis therapeutics market on the basis of drug class, route of administration and region: 

  • Cystic Fibrosis Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2025) 
    • Pancreatic enzyme supplements
    • Mucolytics
    • Bronchodilators
    • CFTR modulators
  • Cystic Fibrosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025) 
    • Oral drugs
    • Inhaled drugs
  • Cystic Fibrosis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Read Our Blog:

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: +1-888-202-9519 Email:


SOURCE Grand View Research, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store